ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
CYP17A1	1586	11358812	-	Polymorphism	-	-	554	184	-	-	-	-	-	[1] The A2 allele of CYP17 decreases endometrial cancer risk; but has only weak effects on endogenous estrogen levels among postmenopausal women. [2] Women with the A2 allele of CYP17 were at decreased risk of endometrial cancer (A1/A1 genotype (reference); A1/A2 genotype: odds ratio; 0.89; 95% confidence interval; 0.62-1.27; A2/A2 genotype: odds ratio; 0.43; 95% confidence interval; 0.23-0.80; P trend; 0.02). The inverse association between the A2 allele and endometrial cancer risk to be stronger among women with a first-degree family history of endometrial and/or colorectal cancer (P for interaction; 0.05).	A polymorphism in CYP17 and endometrial cancer risk	Cancer Research	61(10):3955-60	2001
CYP17A1	1586	20886547	-	Up regulation/ Over expression/High expression	-	-	24	24	-	-	-	-	-	[1] Upregulation of CYP17 in endometrial cancers play a crucial role in endometrial carcinogenesis by targeting multiple components of apoptosis and invasion pathways. [2] Inhibition of CYP17 expression could be a promosing therapeutic approach for treatment of endometrial cancer. [3] Silencing of CYP17 caused decreased cell proliferation and induced apoptosis. Significantly; CYP17 depletion leads to downregulation of anti-apoptotic genes B cell lymphoma 2 (Bcl-2) and telomerase reverse transcriptase (TERT); indicating induced apoptosis. Also; attenuation of CYP17 decreased the cellular invasion ability and regulated expression of several invasion pathway components such as melanoma cell adhesion molecule (MCAM); matrix metallopeptidase 2 and 9 (MMP-2 and MMP-9); and tissue inhibitor of metalloproteinase 3 (TIMP3).	Cytochrome P450 17 (CYP17) is involved in endometrial cancinogenesis through apoptosis and invasion pathways.	Molecular Carcinogenesis	50(1):16-23	2011